192 related articles for article (PubMed ID: 2786379)
1. [Experimental and clinical study of adoptive immunotherapy combined with preadministration of OK-432: a method to augment the therapeutic effect].
Kan N; Okino T; Nakanishi M; Sato K; Mise K; Teramura Y; Yamasaki S; Hori T; Ohgaki K; Tobe T
Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-2):1455-61. PubMed ID: 2786379
[TBL] [Abstract][Full Text] [Related]
2. [Effect of combined immunotherapy using two different BRMs; OK-432 and IL-2-cultured lymphocytes].
Kan N; Hori T; Ohgaki K; Inamoto T; Kodama H; Tobe T
Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 2):1298-306. PubMed ID: 3488027
[TBL] [Abstract][Full Text] [Related]
3. [Augmentation of therapeutic effect of adoptive immunotherapy through a synergy between transferred killer cells and host's fresh lymphocytes].
Kan N; Yamasaki S; Harada T; Satoh K; Ichinose Y; Moriguchi Y; Kodama H; Ohgaki K
Hum Cell; 1992 Sep; 5(3):236-42. PubMed ID: 1467322
[TBL] [Abstract][Full Text] [Related]
4. [Immunotherapy of gastric cancer].
Kan N; Ohgaki K; Okino T; Nakanishi M; Nio Y; Inoue K; Tobe T
Gan To Kagaku Ryoho; 1988 Apr; 15(4 Pt 2-1):755-62. PubMed ID: 3291771
[TBL] [Abstract][Full Text] [Related]
5. [The therapeutic effects of OK-432 combined adoptive immunotherapy (AIT) against liver metastases of breast cancer].
Okino T; Kan N; Nakanishi M; Satoh K; Mise K; Yamasaki S; Teramura Y; Hori T; Kodama H; Ohgaki K
Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-3):1913-9. PubMed ID: 2730083
[TBL] [Abstract][Full Text] [Related]
6. Adoptive immunotherapy in tumor-bearing mice with OK-432-induced killer cells.
Ujiie T
Jpn J Exp Med; 1988 Apr; 58(2):109-14. PubMed ID: 3261814
[TBL] [Abstract][Full Text] [Related]
7. [Transarterial immuno-chemotherapy including adoptive transfer of autologous cultured lymphocytes for stage IV breast cancer patients with locally-advanced tumor].
Kan N; Harada T; Kodama H; Ichinose Y; Moriguchi Y; Sugie T; Li L; Sato K; Imamura M
Gan To Kagaku Ryoho; 1993 Aug; 20(11):1593-6. PubMed ID: 8373227
[TBL] [Abstract][Full Text] [Related]
8. [Successful adoptive immunotherapy with OK432-inducible activated natural killer cells on tumor-bearing mice].
Yamaue H; Tanimura H; Iwahashi M; Tani M; Tsunoda T; Tabuse K
Nihon Gan Chiryo Gakkai Shi; 1989 Dec; 24(11):2546-55. PubMed ID: 2614190
[TBL] [Abstract][Full Text] [Related]
9. [Improved therapeutic effect of sequential immunotherapy with cyclophosphamide, large doses of OK-432 and recombinant interleukin-2 in breast cancer patients with disseminated metastatic liver tumors].
Akimoto M; Nishihira T; Hirakawa H; Abe M; Ohuchi N; Mori S; Kumagai K
Nihon Geka Gakkai Zasshi; 1991 Jan; 92(1):64-74. PubMed ID: 2014029
[TBL] [Abstract][Full Text] [Related]
10. Synergistic therapeutic effect of combination therapy with OK-432 and interferon-alpha or -gamma on Meth-A ascites tumor in BALB/c mice.
Mizushima Y; Morikage T; Hirata H; Sato M; Sakamoto K; Yano S
J Biol Response Mod; 1988 Aug; 7(4):371-83. PubMed ID: 3139841
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic efficacy of sequential therapy with OK-432, cyclophosphamide, IL2-cultured lymphocytes and in vivo IL2 against advanced murine plasmacytoma.
Kan N; Okino T; Nakanishi M; Sato K; Mise K; Yamasaki S; Teramura Y; Ohgaki K; Tobe T
Biotherapy; 1989; 1(3):197-206. PubMed ID: 2642023
[TBL] [Abstract][Full Text] [Related]
12. [Adoptive immunotherapy of murine tumors using cultured syngeneic tumor-bearer-spleen cells. II: Therapeutic effect of cultured lymphocytes against malignant ascites and its augmentation by the streptococcal preparation, OK 432].
Kan N; Inamoto T; Hori T; Nio Y; Tsuchitani T; Kodama H; Tobe T; Ohgaki K
Nihon Gan Chiryo Gakkai Shi; 1985 May; 20(4):784-96. PubMed ID: 3877129
[No Abstract] [Full Text] [Related]
13. [Experimental study on the optimal treatment schedule for combination of BRM (immunostimulators, cultured killer cells or interleukin-2) and chemotherapy].
Kan N; Okino T; Satoh K; Mise K; Teramura Y; Yamasaki S; Harada T; Ohgaki K; Tobe T
Gan To Kagaku Ryoho; 1990 Aug; 17(8 Pt 1):1421-7. PubMed ID: 2389941
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic effect of OK-432 induced endogenous TNF on tumor bearing mice and cancer patients.
Watanabe N; Niitsu Y; Yamauchi N; Neda H; Sone H; Urushizaki I; Yamamoto A; Nagamuta M; Sugawara Y
Immunopharmacol Immunotoxicol; 1988; 10(1):53-65. PubMed ID: 3361071
[TBL] [Abstract][Full Text] [Related]
15. [Clinical value of postoperative chemotherapy for non-small cell lung cancer--with special reference to long-term combined chemotherapy combined with immunotherapy].
Watanabe Y; Sato H; Iida S; Yamada T; Kobayashi H; Kimoto H; Tsunamura Y; Ichihashi T; Shimizu J; Hashizume Y
Gan To Kagaku Ryoho; 1985 Jan; 12(1):21-35. PubMed ID: 2981515
[TBL] [Abstract][Full Text] [Related]
16. [Basic and clinical study of adoptive immunotherapy using cytotoxic T lymphocyte (CTL) against cancers].
Kitsukawa K
Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-2):1448-54. PubMed ID: 2543306
[TBL] [Abstract][Full Text] [Related]
17. [Clinical therapeutic effect of adoptive immunotherapy using IL-2-cultured autologous lymphocytes].
Kan N; Okino T; Nakanishi M; Satou K; Mise K; Ohgaki K; Hori T; Kodama H; Tobe T
Hum Cell; 1988 Sep; 1(3):289-96. PubMed ID: 2979206
[TBL] [Abstract][Full Text] [Related]
18. Combined immunotherapy with intracavital injection of activated lymphocytes, monocyte-derived dendritic cells and low-dose OK-432 in patients with malignant effusion.
Morisaki T; Matsumoto K; Kuroki H; Kubo M; Baba E; Onishi H; Tasaki A; Nakamura M; Inaba S; Katano M
Anticancer Res; 2003; 23(6a):4459-65. PubMed ID: 14666734
[TBL] [Abstract][Full Text] [Related]
19. [Local immunotherapy of breast cancer: a case of advanced breast cancer improved by combined local injection therapy with OK-432 and rIL-2].
Fujimori M; Sugenoya A; Kobayashi S; Masuda H; Komatsu M; Takahashi S; Shimizu T; Tsuchiya S; Iida F
Gan To Kagaku Ryoho; 1989 Aug; 16(8 Pt 2):2760-3. PubMed ID: 2551219
[TBL] [Abstract][Full Text] [Related]
20. Ineffectiveness of adoptive chemoimmunotherapy with lymphokine-activated killer cells, interleukin-2, and cyclophosphamide on palpable intradermal murine bladder cancer.
Lee K; O'Donnell RW; Cockett AT
J Biol Response Mod; 1988 Feb; 7(1):43-53. PubMed ID: 3259620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
